Neoadjuvant radiotherapy for rectal cancer management

Table 3 Studies on watch and wait outcomes, n (%)

Study	n	NA regime	Recurrence	Salvage therapy	Survival post salvage therapy	Survival
Habr-Gama et al[57], 2004	71	Long-course radiotherapy w/ 5-FU	Local:2 Distant: 3	2 (100)	100%	OS: 100% DFS: 92%
Habr-Gama et al[92], 2014	90	Long course radiotherapy w/ 5-FU	Local: 28 (31%)	26 (92.8)	OS: 94%	OS: 91% DFS: 68%
OnCore Project, 2016[59]	129	45 Gy w/ 5-FU	Local: 44 (34%)	36 (88)	N/A	OS: 96% at 3 yr DFS: 88% at 3 yr
IWWD Consortium, 2015[58]	880	Chemoradiotherapy: 91%	Local: 25.2%	141 (69)	OS: 75.4% DFS: 84%	OS: 85% DFS: 94%
Appelt et al[93], 2015	40	Chemoradiotherapy	Local: 25.9% at 2 yr	9	OS: 100% at 2 yr DFS: 100% at 2 yr	OS: 100% at 2 years DFS: 70% at 2 years
Smith et al[94], 2012	32	Long-course chemoradiotherapy	Local: 6 (18.75)	6 (100)	OS: 100% at 17 mo	OS: 96% DFS: 88% all at 17 mo
Smith et al[95], 2019	113		Local: 22 (19.5)	22 (100)	DFS: 91%	OS: 73% DFS: 75%
Martens et al[96], 2016	100	Long-Course: 95% Short Course: 5%	Local: 15% Distant: 5%	13	OS: 92.3%	OS: 96.6% DFS: 80.6% all after 3 yr
Lai et al[97], 2016	18	Chemoradiotherapy	Local: 2	2	100%	OS: 100%
Rijkmans et al[98], 2017	38	External beam radiotherapy and brachytherapy (iridium)				DFS: 42% OS: 63%
Vuong et al[99], 2007	100	External beam radiotherapy with brachytherapy (iridium)	Local recurrence at 5 yr: 5%			DFS: 65% OS: 70%
Gerard et al[100], 2019	74	Contact X-ray brachytherapy	10% at 3 yr	2		DFS: 88%
Sun Myint et al[101], 2018	83	Contact X-ray brachytherapy	13.2% after 2.5 yr (n = 7)	6		DFS: 83.1%
Ortholan et al[63], 2012	45	External beam radiotherapy with contact X-ray boost				DFS: 53% OS: 55%

DFS: Disease-free survival; OS: Overall survival.